



Microthane[®] – Tradition and Innovation

A successful material in the hands of an expert company



POLYTECHinformed[®] is a service offered by:

POLYTECH Health & Aesthetics GmbH
Alzheimer Str. 32 | 64807 Dieburg | Germany

Tel. +49 (0)6071 98 63 0
Fax +49 (0)6071 98 63 30

eMail: info@polytechhealth.com
www.polytech-health-aesthetics.com


Microthane® – Tradition and Innovation

A successful material in the hands of an expert company


William J. Pangman, a genius inventor, had designed a silicone-gel filled implant long before Cronin and Gerow invented theirs in 1962: Pangman's first patent was submitted in 1954 and published on 15 July 1958.

On 11 April 1962, Pangman submitted for patenting an improved variation. It heat-sealed the polyurethane-foam edges around the implant. The corresponding patent was published on 22 June 1965. The technique was in use until the late 1990s.

Submitted on 4 June 1965 and published on 6 February 1968, he designed the first anatomical implant. At the time, cohesive gel was not yet available. Therefore, the implant had been equipped with a support that was formed like an Epsilon. This Y-support and the anatomical shape gave the implant series its name: Natural Y. The product itself was submitted for patenting on 17 October 1968 and the patent published on 2 February 1971. It was later called Optimam®. It is still in use today under the same name, filled with the state-of-the-art highly cross-linked gel.



Pangman patent n°2



Pangman patent n°4



Pangman filed one of his last inventions, an adaptable implant, on 30 January 1970 and it was patented on 15 August 1972.

A very clever medical instruments designer named Hal Markham took Pangman's patent and developed the first Microthane® implants under the names of Mème®, Replicon®, and Optimam®. The production unit that manufactured these implants was called

Aesthetec, the marketing unit adopted the name Natural Y. These companies were represented worldwide by distributors.

In 1986, Cooper Surgical took over Aesthetec and Natural Y and continued distribution through the established channels, adding POLYTECH to their distributor network in that same year.


In 1989 then, Bristol Myer Squibb integrated the distribution into its business. The SBU – strategic business unit – Zimmer took over and the Brazilian distributor was discharged. POLYTECH, however, continued to market the Mème, Replicon, and Optimam implants not only in Germany but all over Europe.

In 1991/92, after the voluntary withdrawal of Bristol Myer Squibb from the breast-implant market, POLYTECH and the former Brazilian distributor decided to cooperate in manufacturing and distributing the polyurethane-covered implants. POLYTECH was to market in Europe, the Soviet Union and the states under the Warsaw Pact, the Brazilian company in the rest of the world.

In Europe, POLYTECH received the first approval to CE-mark their implants as early 1995. This was long before competitors were ready to apply for that certification which became mandatory at the end of the transition period in December 1998.

In 2008, the cooperation between POLYTECH and the Brazilian company was terminated. POLYTECH relocated the complete production to Germany and from then on marketed the implants globally.

Microthane®, Mème®, Replicon®, Optimam®, and Opticon® are registered trademarks of POLYTECH Health & Aesthetics.

 Breast implants made by POLYTECH are quality implants manufactured in Germany.

Natural Y Mème mp
moderate profile mammary implant

The Mème mp® implant represents advanced technology in cross-linked silicone polymers, to ensure optimal placement and maintenance of the implant's natural capabilities of the gel's unique "leak-proof" characteristic. These gel particles make the Mème mp® closer to the fibrous structure of the normal breast than previous implant art. The moderate profile provides greater aesthetic projection and a reduced base per gram weight.


The Mème mp® consists of a porous shell containing a soft cellular structure called "OPTIMAM" and "COGEL" is a porous and granular Mème mp® feature. The cellular relationship to the implant makes Mème mp® highly resistant to infection, fibrous capsule formation, capsular contracture, and other complications. The normal mammography interaction with Mème mp® is the same as the normal breast tissue. It is equally identifiable, non-contrastive microcopy of collagen formation. The Mème mp® implant's porous surface allows the permeability of connective tissue and mammography-compatible formation. Under normal physiological conditions, these interactions ensure the tissue, uncontracted and more cellular capsule configuration present Mème mp® implants.

Mème mp® component configuration and chemistry of implanted foreign material determine healing. The varying architecture and its contracting behavior. Normal completion of the healing process is more likely to result, which optimal cellular interaction is encouraged by the Mème mp®. There is no implant reaction to the implant itself.

Specific gravity and suppleness of the implant closely approximate that of normal breast tissue.

The Mème mp® implant is available in 13 sizes, from 40, 100 grams to 410, 200 grams.

Distributed by:
Natus 23 Surgical Translations Inc.
400 S. 200th Avenue, Suite 200
Libertyville, Illinois 60088
(815) 332-8888



Natural Y REPLICON
higher profile augmentation mammary implant

The REPLICON® implant represents advanced technology in cross-linked silicone polymers, to ensure optimal placement and maintenance of the implant's natural capabilities of the gel's unique "leak-proof" characteristic. These gel particles make the REPLICON® closer to the fibrous structure of the normal breast than previous implant art. The higher profile provides greater aesthetic projection and a reduced base per gram weight.

The same porous shell containing a soft cellular structure called "OPTIMAM" and "COGEL" is a porous and granular REPLICON® feature. The cellular relationship to the implant makes REPLICON® highly resistant to infection, fibrous capsule formation, capsular contracture, and other complications. The normal mammography interaction with REPLICON® is the same as the normal breast tissue. It is equally identifiable, non-contrastive microcopy of collagen formation. The REPLICON® implant's porous surface allows the permeability of connective tissue and mammography-compatible formation. Under normal physiological conditions, these interactions ensure the tissue, uncontracted and more cellular capsule configuration present REPLICON® implants.

Mème mp® component configuration and chemistry of implanted foreign material determine healing. The varying architecture and its contracting behavior. Normal completion of the healing process is more likely to result, which optimal cellular interaction is encouraged by the Mème mp®. There is no implant reaction to the implant itself.

Specific gravity and suppleness of the implant closely approximate that of normal breast tissue.

The REPLICON® implant is available in 18 sizes, from 40, 100 grams to 410, 200 grams.

Distributed by:
Natus 23 Surgical Translations Inc.
400 S. 200th Avenue, Suite 200
Libertyville, Illinois 60088
(815) 332-8888



Natural Y OPTIMAM
full-profile mammary implant

The new OPTIMAM® implant is made in the new OPTIMAM® process for breast augmentation.

The OPTIMAM® provides a unique result in the mammography results of breast imaging. The gel particles make the OPTIMAM® closer to the fibrous structure of the normal breast than previous implant art. The full-profile provides greater aesthetic projection and a reduced base per gram weight.

The same porous shell containing a soft cellular structure called "OPTIMAM" and "COGEL" is a porous and granular OPTIMAM® feature. The cellular relationship to the implant makes OPTIMAM® highly resistant to infection, fibrous capsule formation, capsular contracture, and other complications. The normal mammography interaction with OPTIMAM® is the same as the normal breast tissue. It is equally identifiable, non-contrastive microcopy of collagen formation. The OPTIMAM® implant's porous surface allows the permeability of connective tissue and mammography-compatible formation. Under normal physiological conditions, these interactions ensure the tissue, uncontracted and more cellular capsule configuration present OPTIMAM® implants.

Mème mp® component configuration and chemistry of implanted foreign material determine healing. The varying architecture and its contracting behavior. Normal completion of the healing process is more likely to result, which optimal cellular interaction is encouraged by the Mème mp®. There is no implant reaction to the implant itself.

Specific gravity and suppleness of the implant closely approximate that of normal breast tissue.


The OPTIMAM® implant is available in 17 sizes, from 40, 100 grams to 410, 200 grams, larger sizes available on special order.

POLYTECH Health & Aesthetics
Forststr. 34
D-47163 Altoner 2
D 00 71-73 94-00
Fax 4 188 338 2014





Microthane[®] – Tradition and Innovation



- 1950.....** ▶▶ Ivalon[®] foam
- 1950-1962...** ▶▶ Patent for Microthane[®] implants by John W. Pangman
- 1960's.....** ▶▶ Hall Markham acquires Pangman's patent.
- 1970.....** ▶▶ 1st publication on Microthane[®] by Frank Lloyd Ashley
- 1978.....** ▶▶ Implants produced by Rudi Schulte (Heyer/Schulte)
- 1982.....** ▶▶ Implants produced by Cox Uphoff
- 1987.....** ▶▶ POLYTECH becomes the European distributor for AESTHETECH – Aesthetech being the manufacturer selling via Natural Y.
 - ▶▶ 1st Polyurethane Workshop in Germany
- 1988.....** ▶▶ Launch of the "implant passport" for Microthane[®] implants manufactured for POLYTECH/AESTHETECH
 - ▶▶ Bristol Meyers Squibb acquires all rights from Aesthetech and Natural Y and incorporates the implant business into their medical-devices unit Surgitek.
- 1991-1992...** ▶▶ Bristol Meyers Squibb/Surgitek shuts down all activities, voluntarily, due to the legal situation in the USA.
- 1992.....** ▶▶ POLYTECH acquires all available stock of Microthane[®] implants in order to satisfy the demand on the European market for the time being.
 - ▶▶ POLYTECH collaborates with surgeons in Germany to advance the development of Microthane[®] implants – shell production and filling at the time realized in Brazil.
 - ▶▶ Quality control, packaging and sterilization are executed by POLYTECH in Germany
 - ▶▶ Biocompatibility tests + TDA in-vitro release test
- 1995.....** ▶▶ First company to receive C€ mark approval for class IIb
- 2003.....** ▶▶ First company to receive C€ mark approval for breast implants, since then class III medical devices
- 2008.....** ▶▶ Production of the Microthane[®] implants – Mème[®], Replicon[®], Opticon[®], Optimam[®] – exclusively in Germany and global expansion of sales activities of POLYTECH Health & Aesthetics
 - ▶▶ ISO 13485
 - ▶▶ ISO 9001
 - ▶▶ MDD CE Annex II, Section 3
 - ▶▶ MDD CE Annex II, Section 4
 - ▶▶ ANVISA Inmetro
 - ▶▶ KFDA

